Takeda Demonstrates Long-term Commitment to Antibody Drug Conjugates in Oncology With its Expanded Agreement With Mersana Therapeutics
By Natasha Berry
Pharma Deals Review: Vol 2016 Issue 2 (Table of Contents)
Published: 27 Feb-2016
DOI: 10.3833/pdr.v2016.i2.2144 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In an attempt to bolster its early-stage oncology pipeline and as the company looks to refocus its priorities towards its speciality care interests and away from some of its slowing primary care businesses, Takeda has expanded its pre-existing collaboration with Mersana Therapeutics in a deal that could be worth up to US$830 M for the pre-clinical antibody drug conjugate XMT-1522...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS